OmniTx.ai
From fragmented evidence to defensible decisions - biology-native AI reasoning for high-stakes drug discovery
At a glance
-
Development stage
Prototype developed
-
Investment stage
Pre-Seed
-
Commercialisation pathway
Spinout - staff led
-
Technology readiness level
TRL 4
-
Female led
Yes
OmniTx.ai uses AI to turn complex biomedical evidence into more confident therapeutic decisions.
-
OmniTx.ai bridges the gap between fragmented omics evidence and defensible therapeutic decisions. Its platform combines public and private biomedical evidence, including omics data, human genetics, disease biology, patient context, druggability and safety signals. It then delivers ranked recommendations with reasoning, confidence levels, uncertainty flags and suggested validation steps, all traceable back to the source evidence.
-
Drug discovery is a multi-objective decision problem, yet the evidence driving it remains deeply fragmented across omics (biological data) platforms, AI models, the literature and clinical data. Existing tools address pieces of this landscape but stop short of integrating safety, efficacy, biology and patient context into a coherent, auditable decision.
-
Discovery teams in biotech, pharma, and AI-driven drug discovery companies that translate complex biological data into target, biomarker and stratification decisions.
-
- Strategic partnership in progress with ASX-listed biotech/pharma leaders; active discussions with global players
- Growing pipeline of active customer and data-partner conversations across the sector
- Evidence-reasoning platform benchmarked against SOTA tools, showing measurable performance gains
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.